Biotec Services International, acquired by PCI in September 2014, has completed its rebrand into the PCI group. This rebrand combines the expertise of the two organizations, expanding PCI’s capabilities for global clinical studies.

The expanded range of services includes manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services for clinical package design, global logistics planning and depot managementover a wide range of temperatures from controlled ambient to -196°C.

Dr. Fiona Withey, managing director, UK Clinical Services, said, “The rebranding of Biotec demonstrates to the global pharmaceutical community that by joining the PCI group we are able to offer a significantly increased global capacity to deliver a worldwide offering to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility. We are very excited about the investments PCI has undertaken of late, the acquisition of Biotec and Penn Pharma along with the construction of a new North American Storage, Distribution and Returns Management site, increases the breadth of the PCI service offering and provides our clients significant opportunity to engage with a truly global pharmaceutical services organization.”

Biotec recently completed an expansion to its Bridgend facilities, expanding the footprint of its clinical trial packaging and distribution services, as well as its Cold Chain solutions supporting medicines from +25°C to -196°C.